human glp 1 Glucagon-like peptide-1 receptor agonism and end-organ protection: Trends in Endocrinology & Metabolism GLP-1 actions and target organs.

NT-proBNP, N-terminal probrain natriuretic peptide

Additionally, a multi-country study found substantial demand for GLP-1 medications among people without medical indications, highlighting the evolving landscape of body image and obesity treatment (Jensen et al., 2025)

Van Nieuwenhoven MA, Wagenmakers AJM, Senden JMG, Brouns F, Brummer RJM

Clinical characteristics of patients with GLP-1RA-related hypoglycemia sourced from the FAERS database (from January 2004 to September 2020)

Liver and pancreatic effects Transient increases in liver enzymes (ALT) exceeding three times the upper normal limit occurred in roughly 1% of participants receiving retatrutide